HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED

Altre lingue Hansoh Pharmaceutical Group Company Limited Börse Stuttgart

Azioni

3KY

KYG549581067

Mercato chiuso - Börse Stuttgart Altri mercati azionari 10:40:33 03/07/2024			Variaz. 5gg	Var. 1 gen.
1,86 ^EUR	-1,06%		-2,59%	+9,94%

14/06	Hansoh Pharmaceutical riduce il prezzo di conversione delle obbligazioni convertibili	MT
29/04	Hansoh Pharmaceutical Group Company Limited annuncia cambiamenti nell'esecutivo, con effetto dal 29 aprile 2024	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Hansoh Pharmaceutical Slashes Conversion Price of Convertible Bonds	14/06
Hansoh Pharmaceutical’s 2023 Profit Up 27%	30/04
Hansoh Pharmaceutical Group Company Limited Announces Executive Changes, Effective April 29, 2024	29/04
Hansoh Pharmaceutical Secures Chinese Nod for Trial of Anti-Cancer Drug	03/04
Hansoh Pharmaceutical Group Company Limited, Jiangsu Hansoh Pharmaceutical Group Company Limited and Shanghai Hansoh Biomedical Technology Company Limited Receives Grant of A Clinical Trial Notice Issued by the National Medical Products Administration of the People's Republic of China to Be Used for the Treatment of Advanced Non-Small Cell Lung Cancer	03/04
Hansoh Pharmaceutical Group Company Limited Recommends Final Dividend, Payable on July 17, 2024	26/03
Hansoh Pharmaceutical Group Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	26/03
Hansoh Pharmaceutical Gets Nod to Trial Nephropathy Treatment Capsules	08/02
Hansoh Pharmaceutical Buys Back 3 Million Shares	31/01
Fed, China Property Outlooks Roil Asian Stock Markets	30/01
2023 CTOS, Hansoh Pharma HS-20093 Phase II clinical study design was selected into the International Connective Tissue Oncology Conference	24/01
Hansoh Secures Chinese Nod For Clinical Trial Of Anti-Diabetes Drug	23/01
China Outlook, Tech Rally Roils Asian Stock Markets	19/01
Hansoh Pharmaceutical Units Gets Clinical Trial Notice in China for Schizophrenia Treatment	17/01
Hansoh Pharmaceutical Group Company Limited Announces Clinical Trial Notice of HS-10509 Tablets	17/01
Federal Reserve Outlook Mutes Asian Stock Markets	05/01
Hansoh Pharmaceutical’s Trustee Buys Back Shares	02/01
GSK plc Enters Exclusive License Agreement with Hansoh for HS-20093	20/12
GSK Enters Exclusive License Agreement With Hansoh for HS-20093 Cancer Antibody	20/12
Hansoh Pharmaceutical Grants GSK Subsidiary Marketing License for Tumor Drug HS-20093	20/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Hansoh Pharmaceutical Group Company Limited Börse Stuttgart

Azioni

3KY

KYG549581067

Altre lingue

Filtri